Taf + Emtricitabine + Elvitegravir + Cobicistat Suppliers & Bulk Manufacturers
Available Forms: Tablet
Available Strengths: Elvitegravir – 150 mg + Cobicistat – 150 mg + Emtricitabine – 200 mg + TAF – 10 mg
Reference Brands: Genvoya(US & EU)
Category: Anti Viral
Genvoya is a once-daily HIV-1 treatment combining TAF, Emtricitabine, Elvitegravir, and Cobicistat. It provides strong viral suppression with better kidney and bone safety than older TDF-based options. FDA and EMA approved.
Product Description:
Genvoya is a once-daily, fixed-dose combination of Tenofovir Alafenamide (TAF) 10 mg, Emtricitabine 200 mg, Elvitegravir 150 mg, and Cobicistat 150 mg, used for the treatment of HIV-1 infection. Approved by the US FDA and EMA, Genvoya offers potent viral suppression with improved renal and bone safety compared to older TDF-based regimens like Stribild. It is indicated for treatment-naïve adults and adolescents (≥12 years, ≥35 kg) with no resistance to its components. The inclusion of Cobicistat enhances Elvitegravir and TAF levels, enabling effective once-daily dosing. Genvoya simplifies HIV therapy and improves adherence through its single-tablet formulation.
Taf + Emtricitabine + Elvitegravir + Cobicistat — third party manufacturing & bulk supply
Taf + Emtricitabine + Elvitegravir + Cobicistat is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:
Indicative minimum order quantity
Taf + Emtricitabine + Elvitegravir + Cobicistat is supplied as Tablet — an oral solid dosage form, so the indicative MOQ is 200,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.
Manufacturers of Taf + Emtricitabine + Elvitegravir + Cobicistat listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.
Request a quote for Taf + Emtricitabine + Elvitegravir + Cob... →Frequently Asked Questions
Tenofovir alafenamide + emtricitabine + elvitegravir + cobicistat is used for the treatment of HIV-1 infection. It works as a complete once-daily regimen that suppresses viral replication and helps maintain long-term viral suppression.
It is made from the active ingredients tenofovir alafenamide (TAF), emtricitabine, elvitegravir, and cobicistat. TAF and emtricitabine are nucleoside reverse transcriptase inhibitors, elvitegravir is an integrase inhibitor, and cobicistat is a pharmacokinetic enhancer that boosts elvitegravir levels.
The main trade name is Genvoya in the USA, EU, and UK.
Genvoya is manufactured by Gilead Sciences.
The generic name is tenofovir alafenamide + emtricitabine + elvitegravir + cobicistat.
The primary brand name is Genvoya.
It is manufactured by Gilead Sciences in the USA and EU, along with authorized global manufacturing partners.
Related Products
Brincidofovir
Strength:
100 mg, 10 mg/ml
Form: Tablets / Oral suspension
Reference Brands: Tembexa (USA/EU)
View Details
Lenacapavir
Strength:
300 mg, 463.5 mg/1.5 mL
Form: Tablet / Injection
Reference Brands: Yeztugo (USA), Sunlenca (USA)
View Details
Quick Response Guaranteed | Verified Suppliers
